Skip to content

Study · Animal study (in vivo) · cynomolgus monkey, minipig and rat · 2017

11 results

Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.

Thygesen P, Andersen HS, Behrens C, Fels JJ, Nørskov-Lauritsen L, Rischel C, Johansen NL

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society24 May 2017Cited by 30 (Europe PMC)

PMID28595133 (opens in a new tab)DOI10.1016/j.ghir.2017.05.006 (opens in a new tab)PepBankPUB-28595133
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, subcutaneous somapacitan showed first-order absorption.

    In plain wordsIn rats, somapacitan showed first-order absorption after injection under the skin.

    Peptide
    Somapacitan
    Outcome
    Not applicableAbsorption kinetics
    Study

    Ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (Rat).

    Source sentences

    Summary
    Pharmacokinetic profiles indicated first order absorption from the subcutaneous tissue after s.c. injections for somapacitan in all three species.
    2 context sentences
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In minipigs, subcutaneous somapacitan showed first-order absorption.

    In plain wordsIn minipigs, somapacitan showed first-order absorption after injection under the skin.

    Peptide
    Somapacitan
    Outcome
    Not applicableAbsorption kinetics
    Study

    Minipign: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (Minipig).

    Source sentences

    Summary
    Pharmacokinetic profiles indicated first order absorption from the subcutaneous tissue after s.c. injections for somapacitan in all three species.
    2 context sentences
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In cynomolgus monkeys, subcutaneous somapacitan showed first-order absorption.

    In plain wordsIn monkeys, somapacitan showed first-order absorption after injection under the skin.

    Peptide
    Somapacitan
    Outcome
    Not applicableAbsorption kinetics
    Study

    Cynomolgus monkeyn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    Pharmacokinetic profiles indicated first order absorption from the subcutaneous tissue after s.c. injections for somapacitan in all three species.
    2 context sentences
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, somapacitan apparent terminal half-life was 5-6h.

    In plain wordsIn rats, somapacitan's apparent terminal half-life was 5-6h.

    Peptide
    Somapacitan
    Outcome
    Not applicableApparent terminal half-life
    Study

    Ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Apparent terminal half-life
    5 to 6 h
    rats

    Source sentences

    Summary
    Apparent terminal half-lives were 5-6h in rats, 10-12h in minipigs, and 17-20h in monkeys.
    2 context sentences
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    In minipigs, somapacitan apparent terminal half-life was 10-12h.

    In plain wordsIn minipigs, somapacitan's apparent terminal half-life was 10-12h.

    Peptide
    Somapacitan
    Outcome
    Not applicableApparent terminal half-life
    Study

    Minipign: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Apparent terminal half-life
    10 to 12 h
    minipigs

    Source sentences

    Summary
    Apparent terminal half-lives were 5-6h in rats, 10-12h in minipigs, and 17-20h in monkeys.
    2 context sentences
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  6. 06AnimalAnimal study (in vivo)Pharmacokinetics

    In cynomolgus monkeys, somapacitan apparent terminal half-life was 17-20h.

    In plain wordsIn monkeys, somapacitan's apparent terminal half-life was 17-20h.

    Peptide
    Somapacitan
    Outcome
    Not applicableApparent terminal half-life
    Study

    Cynomolgus monkeyn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Apparent terminal half-life
    17 to 20 h
    monkeys

    Source sentences

    Summary
    Apparent terminal half-lives were 5-6h in rats, 10-12h in minipigs, and 17-20h in monkeys.
    2 context sentences
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In hypophysectomized rats, somapacitan induced dose-dependent growth (p<0.001).

    In plain wordsIn rats without a pituitary gland, somapacitan increased growth as the dose increased.

    Peptide
    Somapacitan
    Outcome
    IncreaseDose-dependent growth
    Study

    Ratn: not reported in source

    Hypophysectomized rats
    Outcome group
    Body weight · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Somapacitan induced a dose-dependent growth in hypophysectomised rats (p<0.001) and an increase in plasma IGF-I levels in rats (p<0.01), minipigs (p<0.01), and cynomolgus monkeys (p<0.05) after single dose administration.
    3 context sentences
    Summary · context
    A dose-response study with five dose levels and a multiple dose pharmacodynamic study with four once weekly doses was performed in hypophysectomised rats to evaluate the effect of somapacitan on growth and IGF-I production.
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats, a single somapacitan dose increased plasma IGF-I (p<0.01).

    In plain wordsIn rats, a single somapacitan dose increased blood IGF-I levels.

    Peptide
    Somapacitan
    Outcome
    IncreasePlasma IGF-I
    Study

    Ratn: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · Single doseAs given in this study (Rat).

    Source sentences

    Summary
    Somapacitan induced a dose-dependent growth in hypophysectomised rats (p<0.001) and an increase in plasma IGF-I levels in rats (p<0.01), minipigs (p<0.01), and cynomolgus monkeys (p<0.05) after single dose administration.
    2 context sentences
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In minipigs, a single somapacitan dose increased plasma IGF-I (p<0.01).

    In plain wordsIn minipigs, a single somapacitan dose increased blood IGF-I levels.

    Peptide
    Somapacitan
    Outcome
    IncreasePlasma IGF-I
    Study

    Minipign: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · Single doseAs given in this study (Minipig).

    Source sentences

    Summary
    Somapacitan induced a dose-dependent growth in hypophysectomised rats (p<0.001) and an increase in plasma IGF-I levels in rats (p<0.01), minipigs (p<0.01), and cynomolgus monkeys (p<0.05) after single dose administration.
    2 context sentences
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In cynomolgus monkeys, a single somapacitan dose increased plasma IGF-I (p<0.05).

    In plain wordsIn monkeys, a single somapacitan dose increased blood IGF-I levels.

    Peptide
    Somapacitan
    Outcome
    IncreasePlasma IGF-I
    Study

    Cynomolgus monkeyn: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · Single doseAs given in this study (Cynomolgus monkey).

    Source sentences

    Summary
    Somapacitan induced a dose-dependent growth in hypophysectomised rats (p<0.001) and an increase in plasma IGF-I levels in rats (p<0.01), minipigs (p<0.01), and cynomolgus monkeys (p<0.05) after single dose administration.
    2 context sentences
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In hypophysectomized rats, repeated weekly somapacitan increased weight stepwise, with linear growth during the first 3-4days of each interval (p<0.001).

    In plain wordsIn rats without a pituitary gland, weekly somapacitan increased weight stepwise, with early linear growth after each dose.

    Peptide
    Somapacitan
    Outcome
    IncreaseBody weight after repeated dosing
    Study

    Ratn: not reported in source

    Hypophysectomized rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · Four once-weekly dosesAs given in this study (Rat).

    Source sentences

    Summary
    Multiple once weekly dosing of somapacitan in hypophysectomised rats induced a step-wise increase in body weight with an initial linear phase the first 3-4days in each dosing interval (p<0.001).
    3 context sentences
    Summary · context
    A dose-response study with five dose levels and a multiple dose pharmacodynamic study with four once weekly doses was performed in hypophysectomised rats to evaluate the effect of somapacitan on growth and IGF-I production.
    Summary · context
    Here we present the pharmacokinetic and pharmacodynamic effects of somapacitan in rats, minipigs, and cynomolgus monkeys.
    Summary · context
    Pharmacokinetic studies investigating exposure, absorption, clearance, and bioavailability after single intravenous (i.v.) and subcutaneous (s.c.) administration were performed in all species.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.